# NIPICOL (NCT03350126)

> iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab

No report yet. It can be ordered.

- Drugs tested: nivolumab plus ipilimumab
- Indication: microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03350126
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
- Conditions: Metastatic Cancer Colorectal
- Interventions: Ipilimumab 200 MG in 40 ML Injection; Nivolumab 10 MG/ML
- Enrollment: 57
- Primary outcome: Disease Control Rate (DCR)

## Indexed commentary on NIPICOL so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nipicol-nct03350126